Genfit S.A. (NASDAQ:GNFT) Short Interest Update

Genfit S.A. (NASDAQ:GNFT - Get Free Report) was the target of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 60,300 shares, a decline of 40.5% from the January 31st total of 101,300 shares. Based on an average trading volume of 8,400 shares, the days-to-cover ratio is presently 7.2 days. Currently, 0.1% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price objective on shares of Genfit in a research note on Friday, February 7th.

Genfit Stock Performance

Shares of GNFT stock traded up $0.07 during mid-day trading on Wednesday, hitting $3.54. The stock had a trading volume of 889 shares, compared to its average volume of 8,705. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. Genfit has a 12-month low of $3.35 and a 12-month high of $6.42. The firm's 50-day moving average is $3.72 and its two-hundred day moving average is $4.39.

Institutional Trading of Genfit

A hedge fund recently bought a new stake in Genfit stock. Millennium Management LLC bought a new position in Genfit S.A. (NASDAQ:GNFT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of Genfit as of its most recent SEC filing. Institutional investors own 2.24% of the company's stock.

Remove Ads

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.